Fotivda
Fotivda ingredients
| Active ingredient | Strength |
|---|---|
| Tivozanib Hydrochloride | .89 mg/1, 1.34 mg/1 |
What Fotivda is used for
The FDA lists the approved uses on the official label (below). In the EU, tivozanib hydrochloride monohydrate is approved as Fotivda for:
Fotivda is indicated for the first line treatment of adult patients with advanced renal cell carcinoma (RCC) and for adult patients who are VEGFR and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced RCC. Treatment of advanced renal cell carcinoma.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Fotivda
- Generic name
- Tivozanib
- Made by
- AVEO Pharmaceuticals, Inc.
- Forms
- Capsule
- Given
- Oral
- Drug class
- Kinase Inhibitor
- FDA approval
- New drug application (NDA) NDA212904
- On the US market since
- 2021
Official information
- MedlinePlus drug information (search for Tivozanib)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Fotivda?
Fotivda (Tivozanib) is a cancer medicine made by AVEO Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Fotivda?
Fotivda contains Tivozanib Hydrochloride (.89 mg/1, 1.34 mg/1).
Is Fotivda approved in Europe?
The same active substance is approved in the EU as Fotivda.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA